Prospective Randomized Trial of Use of In-House Prepared Low-Cost Radiopharmaceutical Versus Commercial Radiopharmaceutical for Sentinel Lymph Node Biopsy in Patients with Early Stage Invasive Breast Cancer
The current standard-of-care for surgical staging of the axilla in clinically node-negative (N0) early breast cancers is sentinel lymph node biopsy (SLNB), which requires expensive radiopharmaceuticals for efficacious results. In-house produced low-cost radiopharmaceuticals may be the solution and have shown efficacy in earlier observational/pilot studies. We compared SLNB using in-house prepared radiopharmaceutical (99mTc-Antimony-colloid) versus commercially marketed radiopharmaceutical (99mTc-Sulphur-colloid) in this prospective randomized study.
78 clinically N0 early breast cancer patients (T1/2, N0 stages), undergoing primary surgery were prospectively randomized 1:1 into two groups; to receive SLNB using methylene blue, and either 99mTc-Antimony colloid (Group-1) or 99mTc-Sulphur colloid (Group-2). Completion axillary dissection was done in all (validation SLNB). SLNB indices were compared between the groups.
The groups were comparable with regard to age, stage, tumour size, hormone receptors and HER2neu status. Cost of the in-house prepared 99mTc-antimony colloid was 16-times lesser compared to 99mTc-sulphur colloid. SLN identification rates (IR) in Groups 1 and 2 were 100 and 97.4% respectively, (p > 0.05). False negative rates (FNR) in Group 1 and 2 were 6.3% (1/16 patients) and 7.7% (1/13 patients), respectively, (p > 0.05). There were no major allergic reactions in either group.
In this prospective randomized trial on early breast cancer patients, accuracy of SLNB was comparable using in-house prepared, 99mTc-antimony colloid and commercially marketed 99mTc-sulphur colloid as radiopharmaceutical, while 99mTc-antimony colloid was much cheaper than 99mTc-sulphur colloid.
This prospective study was made possible with the aid of a SGPGIMS Intramural Grant. The authors would also like to acknowledge the Resident Surgeons of the Department of Endocrine and Breast Surgery, SGPGIMS, Lucknow; and Mr. Subhash Kheruka of the Department of Nuclear Medicine, SGPGIMS, Lucknow for their help.
Compliance with ethical standards
Conflict of interest
- 2.Krag DN, Anderson SJ, Julian TB et al (2007) Technical outcomes of sentinel-lymph node resection and conventional axillary-lymph-node dissection in patients with clinically node-negative breast cancer: results from the NSABP B-32 randomised phase III trial. Lancet Oncol 8:881–888CrossRefPubMedGoogle Scholar
- 5.Fitzgibbons PL, Page DL, Weaver D et al (1999) Prognostic factors in breast cancer. College of American Pathologists consensus statement. Arch Pathol Lab Med 124:966–978Google Scholar
- 6.Lyman GH, Temin S, Edge SB et al (2014) American Society of Clinical Oncology Clinical Practice. Sentinel lymph node biopsy for patients with early-stage breast cancer: American Society of Clinical Oncology clinical practice guideline update. J Clin Oncol 32(13):1365–1383CrossRefPubMedGoogle Scholar
- 8.Agarwal G, Gambhir S, Kheruka S et al (2005) Low-cost sentinel node studies in breast cancer with indigenous blue dye & 99mTc-antimony colloid. J Japan Surg Soc 106:221Google Scholar
- 9.National Comprehensive Cancer Network. Breast Cancer (Version 1.2017). http://www.nccn.org/professionals/physician_gls/pdf/breast.pdf. Accessed 1 January 2017
- 14.Hinkle GH. Lymphoscintigraphy and sentinel node biopsy in the staging of cancer (Correspondence Continuing Education Courses for Nuclear Pharmacists and Nuclear Medicine Professionals, Volume 11, Lesson 6). http://pharmacyce.unm.edu/nuclear_program/freelessonfiles/Vol11Lesson6.pdf. Accessed 12 January 2017
- 17.Sadeghi R, Zakavi SR, Forghani MN et al (2010) The efficacy of Tc-99m sestamibi for sentinel node mapping in breast carcinomas: comparison with Tc-99m antimony sulphide colloid. Nuclear Med Rev 13(1):1–4Google Scholar